Analytical Data
-
Gene name
Beta-glucuronidase/GUSB
- Application
-
Alternative Names
GUS-B; MPS7; Beta-G1
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P12265
-
Expression Region
Ala451~Phe648
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Beta-glucuronidase (GUSB) is an important lysosomal enzyme responsible for the hydrolysis of glucuronides, which are conjugates formed by the attachment of glucuronic acid to various substances, including drugs and endogenous metabolites. Deficiency of GUSB leads to the lysosomal storage disorder known as mucopolysaccharidosis type VII (MPS VII), characterized by the accumulation of glycosaminoglycans in lysosomes, resulting in various clinical manifestations ranging from skeletal abnormalities to neurological impairment. The study of recombinant GUSB has gained significant attention as a potential therapeutic approach for MPS VII. By utilizing techniques such as recombinant DNA technology, researchers can produce functional GUSB in various expression systems, including yeast, bacteria, and mammalian cells. This production not only enhances our understanding of the enzyme's structure and function but also facilitates the development of enzyme replacement therapies (ERT) aimed at restoring GUSB levels in affected individuals. Additionally, the investigation of GUSB has broader implications in pharmacology and toxicology, as it plays a critical role in drug metabolism and clearance. The continued research on GUSB and recombinant protein production not only holds promise for treating MPS VII but also contributes to the growing field of enzyme-based therapies for a range of metabolic disorders.
